Guest Editor(s)
Dr. Roberto Contieri
Email: contieri.ro@gmail.com
Affiliation: Urology Department, National Cancer Institute, IRCCS "G. Pascale", Naples, Italy
Homepage:
Research Interests: urothelial carcinoma, uro-oncology
Prof. Dr. Sisto Perdonà
Email: s.perdona@istitutotumori.na.it
Affiliation: Urology Department, National Cancer Institute, IRCCS "G. Pascale", Naples, Italy
Homepage:
Research Interests: urologic oncology, robotic surgery, bladder cancer
Summary
NMIBC represents a biologically heterogeneous disease spectrum, ranging from indolent LG tumors to aggressive HG lesions with substantial risks of recurrence, progression, and treatment failure. Recent advances have reshaped several aspects of NMIBC management, including improved diagnostic pathways, enhanced endoscopic imaging, optimized TURBT quality, refined risk stratification, and a growing emphasis on personalized treatment selection. At the same time, the therapeutic landscape is rapidly evolving beyond conventional intravesical chemotherapy and BCG, with increasing interest in novel drug-delivery systems, immunotherapeutic strategies, gene therapy, targeted agents, and bladder-preserving approaches for selected patients.
This Special Issue, "Advances in Non-Muscle-Invasive Bladder Cancer: From Diagnosis to Novel Therapies," aims to provide a comprehensive overview of contemporary developments across the NMIBC disease pathway. Topics of interest include innovations in cystoscopic detection, urinary biomarkers, molecular classification, AI-based tools, surgical quality improvement, risk-adapted surveillance, BCG optimization, management of BCG-unresponsive disease, and emerging intravesical or systemic treatment strategies. Contributions addressing real-world implementation, clinical trial design, patient-reported outcomes, and de-intensification or escalation strategies are also welcome.
By integrating diagnostic, surgical, biological, and therapeutic perspectives, this Special Issue seeks to highlight current challenges and future directions toward more precise, effective, and patient-centered NMIBC care.
Keywords
non muscle invasive bladder cancer, immunotherapy, BCG, urothelial carcinoma
Login
Register
Submit a Paper
Propose a Special lssue